Covid-19 Research

Review Article

The Altered Gene Expression and Epigenetic Mechanisms in Breast Cancer

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Review Article
Subject Medicine Group
OCLC JBRES Record
Nameera Parveen Shaikh, Ia Murvanidze, Aleena Parveen Shaikh, Rajneesh Khurana and Irina Nakashidze*
Issue: Volume4-Issue10
Pages: 1461-1469
Received: 2023-10-13
Accepted: 2023-10-23
Published: 2023-10-25

Abstract

Among oncological diseases of women, breast cancer is a widespread disease. It should be noted that the disease is heterogeneous in many clinical and pathological features. The development of breast cancer is associated with many factors, and it is difficult to identify any specific risk factor. The studying the expression and epigenetic mechanisms of genes associated with breast cancer, it is possible to effectively combine epigenetic therapy with the existing one in clinical practice (chemotherapy, hormonal therapy, etc.) and accordingly, the treatment of disease is significantly improved.

FullText HTML FullText PDF DOI: 10.37871/jbres1819 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2023 Shaikh NP, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Shaikh NP, Murvanidze I, Shaikh AP, Khurana R, Nakashidze I. The Altered Gene Expression and Epigenetic Mechanisms in Breast Cancer. J Biomed Res Environ Sci. 2023 Oct 25; 4(10): 1461-1469. doi: 10.37871/jbres1819, Article ID: JBRES1819, Available at: https://www.jelsciences.com/articles/jbres1819.pdf

Subject area(s)

OncologyCancer

References

  1. Nakashidze I, Kotrikadze N, Diasamidze A, Nagervadze M, Alibegashvili M, Ramishvili L, Gordeziani M. Erythrocyte blood group antigens and alterations of the hormonal status among the reproductive age women with breast tumors. Eur Med Health Pharm J. May 2014;7(1). doi: 10.12955/emhpj.v7i1.429.
  2. Cataldi S, Arcuri C, Lazzarini A, Nakashidze I, Ragonese F, Fioretti B, Ferri I, Conte C, Codini M, Beccari T, Curcio F, Albi E. Effect of 1α,25(OH)2 Vitamin D3 in Mutant P53 Glioblastoma Cells: Involvement of Neutral Sphingomyelinase1. Cancers (Basel). 2020 Oct 28;12(11):3163. doi: 10.3390/cancers12113163. PMID: 33126474; PMCID: PMC7694157.
  3. Kotrikadze N. 255 The study of the antioxidant enzymes, the activity of acid phosphatase and alteration of lipid peroxidation in women with uterine tumors. E-Poster. 2019;A108.3-A109. doi: 10.1136/ijgc-2019-IGCS.255.
  4. Kotrikadze N, Tufinashvili T, Ramishvili L, Alibegashvili M, Nakashidze I, Nemsadze G, Gordeziani M, Khazaradze A, Sepiashvilli B, Ahmad S. Differential assessments of blood lipids, lipid peroxidation, antioxidant status, and fatty acids in women with uterine tumors during menopausal period. FASEB J. 2019;33(S1). doi: 10.1096/fasebj.2019.33.1_supplement.796.18.
  5. Kotrikadze N, Tufinashvili T, Nakashidze I, Ramishvili L, Alibegashvili M, Gordeziani M, Sepiashvilli B, Ahmad S. Morpho‐structural peculiarities of blood formed elements and clinic‐pathological characteristics in women with uterine (Benign, Malignant) tumors in menopausal age. FASEB J. 2019;33(S1). doi: 10.1096/fasebj.2019.33.1_supplement.495.7.
  6. Kotrikadze N, Alibegashvili M, Ramishvili L, Nakashidze I, Tevdoradze T, Gordeziani M, Zibzibadze M, Khazaradze A, Sepiashvilli B, Ahmad S. Thermodynamic parameters of blood plasma proteins in women with breast tumors. Gynecol Oncol. 2020;159:357. doi: 10.1016/j.ygyno.2020.05.671.
  7. Kotrikadze N, Bochorishvili I, Alibegashvili M, Ramishvili L, Nakashidze I, Chigogidze T, Gordeziani M, Khazaradze A, Sepiashvili B, Gabunia N, Monaselidze J, Ahmad S. Alterations in physicochemical characteristics of blood plasma in men with prostate tumors 2021;59(05):285-293.
  8. Nakashidze I, Ahmad S. Genetic predisposition for pancreatic cancer. Theranostic Approach for Pancreatic Cancer. 2019;153-169. doi: 10.1016/B978-0-12-819457-7.00008-6.
  9. Nakashidze I, Dariya B, Peshkova T, Beridze S. The Genetic Polymorphisms in Colon Cancer. Crit Rev Oncog. 2020;25(4):405-415. doi: 10.1615/CritRevOncog.2020035957. PMID: 33639065.
  10. Ungiadze J, Zamtaradze N, Samnidze K, Ungiadze D, Nakashidze I. EPV134/#557 The study of some clinico-genetic characteristics in pregnant women with uterine leiomyomas. E-Posters. 2021;A83.2-A83. doi: 10.1136/ijgc-2021-IGCS.204.
  11. Shaikh AP, Shaikh NP, Irina N. VDR gene SNPs in gastrointestinal tumors. JSM Gastroenterol Hepatol. 2022;9(2). doi: 10.47739/2373-9487/1111.
  12. Nakashidze I, Petrović N, Kedelidze N, Dariya B. Clinical significance of genetic variants in colon cancer. Colon Cancer Diagnosis and Therapy. 2022;3:69-91. doi: 10.1007/978-3-030-72702-4_4.
  13. Shi Y, Zhang H, Huang S, Yin L, Wang F, Luo P, Huang H. Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2022 Jun 25;7(1):200. doi: 10.1038/s41392-022-01055-2. PMID: 35752619; PMCID: PMC9233709.
  14. Shaikh AP, Khurana R, Shaikh NP, Barua JD, Ali DA, Ia Murvanidze, Saralidze E, Nakashidze I. Peculiarities of some candidate gene polymorphisms in Parkinson’s disease. Pomeranian J Life Sci. 2023;69(2):22-27. doi: 10.21164/pomjlifesci.893.
  15. Jin X, Mu P. Targeting Breast Cancer Metastasis. Breast Cancer (Auckl). 2015 Sep 1;9(Suppl 1):23-34. doi: 10.4137/BCBCR.S25460. PMID: 26380552; PMCID: PMC4559199.
  16. Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol. 2018 Aug;51:22-35. doi: 10.1016/j.semcancer.2018.01.007. Epub 2018 Jan 12. PMID: 29339244.
  17. Teschendorff AE, Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, Fasching PA, Widschwendter M. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat Commun. 2016 Jan 29;7:10478. doi: 10.1038/ncomms10478. PMID: 26823093; PMCID: PMC4740178.
  18. Bird A. Perceptions of epigenetics. Nature. 2007 May 24;447(7143):396-8. doi: 10.1038/nature05913. PMID: 17522671.
  19. Lustberg MB, Ramaswamy B. Epigenetic Therapy in Breast Cancer. Curr Breast Cancer Rep. 2011 Mar;3(1):34-43. doi: 10.1007/s12609-010-0034-0. PMID: 23097683; PMCID: PMC3477864.
  20. Rahman MM, Brane AC, Tollefsbol TO. MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer. Cells. 2019 Oct 8;8(10):1214. doi: 10.3390/cells8101214. PMID: 31597272; PMCID: PMC6829616.
  21. Budakoti M, Panwar AS, Molpa D, Singh RK, Büsselberg D, Mishra AP, Coutinho HDM, Nigam M. Micro-RNA: The darkhorse of cancer. Cell Signal. 2021 Jul;83:109995. doi: 10.1016/j.cellsig.2021.109995. Epub 2021 Mar 27. PMID: 33785398.
  22. Tiberio P, Gaudio M, Belloni S, Pindilli S, Benvenuti C, Jacobs F, Saltalamacchia G, Zambelli A, Santoro A, De Sanctis R. Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023 Jun 30;15(13):3424. doi: 10.3390/cancers15133424. PMID: 37444533; PMCID: PMC10340268.
  23. Koopaie M, Abedinejad F, Manifar S, Mousavi R, Kolahdooz S, Shamshiri A. Salivary miRNA-21 expression as a potential non-invasive diagnostic biomarker in breast cancer. Gene Rep. 2021;25. doi: 10.1016/j.genrep.2021.101317.
  24. Petrovic N, Sami A, Martinovic J, Zaric M, Nakashidze I, Lukic S, Jovanovic-Cupic S. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. Pathol Res Pract. 2017 Oct;213(10):1264-1270. doi: 10.1016/j.prp.2017.08.012. Epub 2017 Sep 6. PMID: 28935174.
  25. Petrović N, Nakashidze I, Nedeljković M. Correction to: Breast Cancer Response to Therapy: Can microRNAs Lead the Way? J Mammary Gland Biol Neoplasia. 2021 Jun;26(2):179. doi: 10.1007/s10911-021-09480-9. Erratum for: J Mammary Gland Biol Neoplasia. 2021 Jun;26(2):157-178. PMID: 33590361.
  26. Liu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan L, Andrews R, Zhong W, Zhang X, Song E, Gong C. Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death Dis. 2019 Jan 22;10(2):55. doi: 10.1038/s41419-018-1287-1. PMID: 30670688; PMCID: PMC6343010.
  27. Xiu B, Chi Y, Liu L, Chi W, Zhang Q, Chen J, Guo R, Si J, Li L, Xue J, Shao ZM, Wu ZH, Huang S, Wu J. LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription. Mol Cancer. 2019 Dec 19;18(1):187. doi: 10.1186/s12943-019-1115-y. PMID: 31856843; PMCID: PMC6921600.
  28. Acun T, Senses KM. Downregulation of DNAJC10 (ERDJ5) is associated with poor survival in breast cancer. Breast Cancer. 2020 May;27(3):483-489. doi: 10.1007/s12282-019-01042-6. Epub 2020 Jan 4. PMID: 31902119.
  29. Wang L, Sun J, Yin Y, Sun Y, Ma J, Zhou R, Chang X, Li D, Yao Z, Tian S, Zhang K, Liu Z, Ma Z. Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells. Cell Death Dis. 2021 Feb 4;12(2):149. doi: 10.1038/s41419-021-03442-z. PMID: 33542201; PMCID: PMC7862277.
  30. Wang Y, Pan X, Li Y, Wang R, Yang Y, Jiang B, Sun G, Shao C, Wang M, Gong Y. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis. J Pathol. 2021 Jun;254(2):185-198. doi: 10.1002/path.5657. Epub 2021 Apr 9. PMID: 33638154.
  31. Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15. PMID: 27979916; PMCID: PMC5457329.
  32. Huang J, Li J, Tang J, Wu Y, Dai F, Yi Z, Wang Y, Li Y, Wu Y, Ren G, Xiang T. ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance. Int J Biol Sci. 2022 Apr 4;18(7):2833-2850. doi: 10.7150/ijbs.70544. PMID: 35541896; PMCID: PMC9066102.
  33. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6. PMID: 27269946.
  34. Ye L, Lin C, Wang X, Li Q, Li Y, Wang M, Zhao Z, Wu X, Shi D, Xiao Y, Ren L, Jian Y, Yang M, Ou R, Deng G, Ouyang Y, Chen X, Li J, Song L. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO Mol Med. 2019 Dec;11(12):e10638. doi: 10.15252/emmm.201910638. Epub 2019 Oct 28. Erratum in: EMBO Mol Med. 2022 Mar 7;14(3):e15618. PMID: 31657150; PMCID: PMC6895605.
  35. Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, Duckett DR. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Nov 11;36(5):545-558.e7. doi: 10.1016/j.ccell.2019.09.004. Epub 2019 Oct 24. PMID: 31668947.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership